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‘Superbugs’, bacteria that have become resistant to antibiotics, have been in numerous media headlines, raising
awareness of antibiotic resistance and leading to multiple action plans from policymakers worldwide. However,
many commonly used terms, such as ‘the war against superbugs’, risk misleading people to request ‘new’ or
‘stronger’ antibiotics from their doctors, veterinary surgeons or pharmacists, rather than addressing a funda-
mental issue: the misuse and overuse of antibiotics in humans and animals. Simple measures of antibiotic con-
sumption are needed for mass communication. In this article, we describe the concept of the ‘antibiotic footprint’
as a tool to communicate to the public the magnitude of antibiotic use in humans, animals and industry, and
how it could support the reduction of overuse and misuse of antibiotics worldwide. We propose that people need
to make appropriate changes in behaviour that reduce their direct and indirect consumption of antibiotics.
Introduction
Antibiotic resistance is an increasingly serious threat to public
health. When bacteria can stop an antibiotic from working against
them, standard antibiotic treatments become ineffective and
infections with antibiotic-resistant bacteria are associated with a
higher risk of death. Hundreds of thousands of deaths per year are
estimated to be attributable to antibiotic resistance.1 That number
is likely to rise to many millions per year by 2050. The misuse and
overuse of antibiotics is a key contributor to this problem.
Antibiotics consumed by humans and animals are often excreted
as active drugs (that is, the body does not deactivate them), and
these enter the sewage systems and water sources, where they
select for antibiotic-resistant bacteria in the environment.1
International health organizations encourage all countries to
reduce their use of antibiotics in both humans and animals to a
minimum, but limited public understanding of antibiotic resistance
and its drivers is likely to be a major barrier to the reduction of in-
appropriate antibiotic use.2 Antibiotics are often inappropriately
used to treat viral infections in humans, including the common
cold. A large number of people worldwide incorrectly believe that
antibiotics are effective for the common cold and influenza-like ill-
nesses.3,4 A recent study in the UK found that antibiotic resistance
information given to participants with low awareness could, para-
doxically, lead them to ask a doctor for antibiotics more often.5
Therefore, communication messages on antibiotic resistance
should be simple,5 and individuals need to be supported to under-
stand that appropriate behaviour change is important to them per-
sonally.6 In addition, antibiotics are used in large quantities in
agriculture to maintain animal health, and in industry and house-
hold products for reasons largely unrelated to human health.7
Consumers are in a strong position to influence the use of
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antibiotics everywhere. But access to usage volumes and usage
patterns is limited and consumers are poorly informed about exist-
ing use, which reduces the impetus for change.
Antibiotic footprint
The ‘antibiotic footprint’ has been proposed as a global tool for the
public communication of the magnitude of antibiotic use in
humans, animals and industry,8 which could build on the success
of the concept of the carbon footprint. People need to use energy
to live, but using too much energy has been driving climate change
globally. Likewise, people and animals need antibiotics if they are
infected with bacteria. However, overuse and misuse of antibiotics
in humans and animals are fostering antibiotic-resistant bacteria,
and will increase the global number of human and animal deaths
they cause over time.1 The antibiotic footprint could serve as a tool
to better inform people of the widespread and often unnecessary
use of antibiotics, which could help to reduce their use locally and
globally, and in turn reduce the risk of antibiotic-resistant bacteria
and, potentially, infections with antibiotic-resistant bacteria.
Below, we discuss the similarity between the antibiotic footprint
and the carbon footprint, and potential uses of the antibiotic
footprint.
Carbon footprint as a model
Just as reducing the carbon footprint to a minimum is the goal, the
aim of the antibiotic footprint would be to reduce antibiotic con-
sumption to a minimum. Clear ways of communicating this to the
public are important in tackling both climate change and antibiotic
resistance. Formerly, the research community used life cycle as-
sessment (LCA) as an indicator of climate change potential.9 LCA
was intended to create a holistic picture, provide information
about the consequences of change, and inform policy makers.
Subsequently, the term ‘carbon footprint’ was adopted, mainly by
pro-active non-governmental organizations (NGOs) and the pri-
vate sector. This concept is catchy, simple to understand and easy
to calculate on-line, and retail chains and companies proactively
request and provide such information to consumers.9
As a carbon footprint measures the quantity of gaseous emis-
sions relevant to climate change and is associated with activities
such as automobile use, building heating and agriculture
(Figure 1), an antibiotic footprint can be used to attribute antibiotic
consumption to different human activities. This includes direct
consumption of antibiotics at community and hospital levels, and
indirect consumption, for example via animals bred for food. The
antibiotic footprint also aligns with the concept of One Health since
the antibiotic footprint considers antibiotic consumption in all sec-
tors, including humans and animals.
Simple measures of consumption are needed; carbon emis-
sions are measured in units of mass of carbon dioxide and
antibiotic consumption could be measured in units of mass of anti-
biotics as a total value or per head of population. Currently, many
indicators are proposed and used for antibiotic consumption in
human and animals, including the DDD per 1000 inhabitants per
day and milligrams per population correction unit (PCU).10,11 These
terms were created to support fair comparisons among different
antibiotics and different animals included in the calculation, but
are complex terms. Learning from the carbon footprint, it is likely
to be better to design the public communication strategy around
antibiotic consumption in simple terms of mass of antibiotics.
Nation-level carbon footprint data are now widely and openly
available, with tools for their easy visualization. In comparison, the
majority of national data across all sectors (humans and animals)
on antibiotic consumption come from high-income countries.12–14
National data on antibiotic consumption for human use in low-
and middle-income countries (LMICs) are becoming increasingly
available,15 but national data on consumption for animal use in
LMICs is rarely available.16 Complete data on antibiotic usage in
each sector should be made openly available so that multiple met-
rics (such as total consumption, DDD, mg/PCU, mg/kg, daily dose
metrics and course dose metrics)10,11 of each antibiotic (particular-
ly of the highest-priority critically important antibiotics)17 can be
estimated and used by clinicians, farmers, researchers and policy-
makers. Then, the increasing information on complete antibiotic
use in each country (and all metrics and research evidence on anti-
biotic resistance) would allow the communication strategy to be
adjusted and improved over time.
Potential uses of antibiotic footprint
Similar to the carbon footprint, the antibiotic footprint of each
country with official data could be presented and compared
(Figure 2). This information would inform both policymakers and
the community. For example, we might define a country’s antibiot-
ic footprint as the total amount of antibiotics consumed in that
country. The antibiotic footprint could be estimated by combining
the total amount of antibiotics consumed by humans and animals
in a given country (Figure 3). Consequently, the antibiotic footprint
per capita (person) could also be estimated. While it is true that
antibiotic use in animal agriculture would increase or decrease de-
pending on the total amount of livestock being raised in the coun-
try, it is also true that countries that only import meat and do not
raise any animals will not have antibiotics excreted from animals
into the environment. This is why we propose using total consump-
tion by country (Figure 3).
These data visualizations (Figures 2 and 3) can also prompt peo-
ple to ask ‘How much antibiotic is being used in countries without of-
ficial data?’. It is worth noting that official data on antibiotic
consumption in many LMICs (including India and China) are currently
not available.15 However, research evidence suggests that antibiotic
consumption in human and animals in these countries is high.18,19
Clearly, crude comparisons of the antibiotic footprint do not
take account of variations in populations, risk factors for infections
and different farming practices. However, data can be used to
prompt people to ask questions, such as ‘I didn’t know that so
much antibiotic was used in food production—is this being
reduced?’. For example, in 2013, total antibiotic consumption in
the UK was 957 tonnes, of which 521 tonnes (55%) was for direct
human consumption and 436 tonnes (45%) was for animal use.20
When compared with 2013, the total consumption for human use
in 2017 decreased by 6% to about 491 tonnes, while the total anti-
biotic consumption for animal use in 2017 decreased by 35% to
282 tonnes (Figure 3).20 Of the 491 tonnes used in humans, it was
estimated that 20% was used in the hospital sector and 80% in
the community (primary care sector).20
Crude comparison of average consumption per capita could also
prompt people to ask whether misuse and overuse of antibiotics
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occur. For example, worked out as an average per head of popula-
tion in 2015, a person living in the UK is directly consuming twice as
much antibiotic as a person living in the Netherlands (8.3 versus
3.3 g, respectively).15 This is supported by the comparison of DDD
per 1000 inhabitants per day between the two countries (20.47 ver-
sus 9.78, respectively).15 It is unlikely that a higher incidence of bac-
terial infections in the human population accounts for this
difference; differences in healthcare systems, patient expectations
and attitudes to taking antibiotics are the likely major contributors.
The large difference between average consumption of antibiotics
per capita in the UK and Spain in 2015 (14.3 versus 72.6 g; Figure 2b)
is largely because the total consumption of antibiotics in animals in
the UK is much lower than that in Spain (395.1 versus 3027.7
tonnes, respectively). Data on mg/PCU suggest that livestock farm-
ing in Spain used about six times more antibiotics (per 1 kg of bio-
mass) than livestock farming in the UK.12
National data for antibiotics discharged directly into the envir-
onment, for example by pharmaceutical companies, are still large-
ly unavailable worldwide.21 However, research has shown that
there can be considerable environmental contamination during
antibiotic production in some countries.21 The AMR Industry
Alliance (www.amrindustryalliance.org) is working to improve this.
The quantity of environmental contamination could also be added
to a country’s total consumption data where available.
An antibiotic footprint could also be calculated for individuals.
As antibiotic use in humans varies by age, gender, local culture and
individual attitude to taking antibiotics, etc., it would be inform-
ative to compare ourselves with other people in our own country,
as well as other countries. Similar to on-line calculators for the car-
bon footprint, on-line individual calculators for antibiotic footprint
could provide information, knowledge and recommendations
about antibiotic consumption that could influence individual be-
haviour change, such as the impact of hand hygiene, vaccination
and considered food choices.
The antibiotic footprint could be a tool to support global targets
for reducing antibiotic consumption. The carbon footprint has been
an important tool to support global targets to reduce carbon emis-
sions. Progress in reducing global antibiotic consumption and that
of individual countries is poorly described or defined. For example,
colistin is currently considered as a last defence against some MDR
Figure 1. A conceptual figure for carbon footprint and antibiotic footprint. The figure shows a holistic approach to the carbon footprint (left) and
antibiotic footprint (right). The antibiotic footprint is defined as the total amount of antibiotic consumption that is associated with human activities,
including direct consumption of antibiotics by humans at community and hospital levels and consumption by animals. The figure is reproduced
from www.antibioticfootprint.net under the terms of the Creative Commons Attribution 4.0. This figure appears in colour in the online version of
JAC and in black and white in the print version of JAC.
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Figure 2. Examples of antibiotic footprint (a) by country (metric tonnes) and (b) per capita (grams per person) in 2015 based on official and open-
access data for the countries shown. Only official and open-access data from each country were used. Antibiotic consumption data in humans
were based on open-access official data in the WHO Report on Surveillance of Antibiotic Consumption.15 Data on antibiotic consumption in animal
agriculture were based on the annual report of the World Organization for Animal Health (OIE).14 Data are available for the year 2015 from the
European Surveillance of Veterinary Antimicrobial Consumption (ESVAC), the US FDA, the Agricultural and Livestock Service, Chile (SAG), and the
Ministry of Agriculture, Forestry and Fishery, Japan (MAFF).14 Of 62 countries with official data on antibiotic consumptions in 2015, 25 (40%) had
data across all sectors (humans at community and hospital levels and animals). Those included Japan and 24 European countries.14,15 The figure
is reproduced from www.antibioticfootprint.net under the terms of the Creative Commons Attribution 4.0. This figure appears in colour in the online
version of JAC and in black and white in the print version of JAC.
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infections. In 2016, the EU set a target for desirable levels of colis-
tin use in food-producing animals between 5 and 1 mg/PCU.22
This goal is not yet agreed as a global target. In addition, official
data for colistin consumption in LMICs are still largely unavailable.
Setting targets for antibiotic consumption will be difficult because
this combines the reduction of inappropriate use, whilst not dis-
couraging appropriate use and access for those people and ani-
mals that need them. Nonetheless, it is possible that the antibiotic
footprint concept could support implementation of future global
targets.
How do we reduce our antibiotic footprint?
People can reduce their own antibiotic footprint to a minimum by
adjusting their activities and behaviour. This could include interven-
tions to reduce infection risk such as ensuring uptake of available
vaccinations, improving hand and food hygiene, and keeping
healthy through following recommended exercise and dietary guid-
ance.23 Diagnostic tests or scoring systems could also reduce in-
appropriate antibiotic prescribing (particularly for the common cold
or acute sore throat using the low FeverPAIN score or Centor
score).24 If the incidence of infectious diseases declines, opportuni-
ties for both appropriate and inappropriate antibiotic consumption in
the whole population will also decline. Healthcare providers should
continue to improve antibiotic stewardship and infection control in
both hospitals and the community. Improved sanitation and water
supplies in many developing countries will make a major difference.
Antibiotic use in food production can be lowered by promoting
good animal husbandry standards. In 2017, UK supermarkets
Asda, Waitrose and Marks & Spencer published farm-level antibiot-
ic use data.25,26 This represents a major step in retailer transpar-
ency. Nonetheless, changing human behaviour is complex. Food
labelling is contentious because food should not contain antibiotics
at the point of sale, even if they have been used in the production
process. Terms such as ‘antibiotic-free’ and ‘organic’ can be mis-
leading, especially as there is no global agreement on their defin-
ition. Furthermore, animal welfare may be compromised where
these terms are being used. Further studies and evaluations on
communication and implementation of reducing overuse and mis-
use of antibiotics are needed. Licensing authorities should ensure
that both the manufacture of active pharmaceutical ingredients
and their assembly into antibiotic products do not cause environ-
mental contamination.
The antibiotic footprint also has limitations. The availability of
open-access data on national antibiotic consumption in human
and animal sectors in LMICs is still limited. For the carbon footprint,
different types of energy source may have different impacts on cli-
mate change, and a formula using emission factors (for example,
for methane and ammonia) to standardize carbon emission is
needed.27–29 Similarly, methods to compare antibiotic consump-
tion in human and animal sectors and for different types of antibi-
otics will also be needed in the future. The effects of
communication of the antibiotic footprint to people also need fur-
ther testing.
Conclusions
We propose that the antibiotic footprint could be one of a suite of
tools to communicate information to the community on antibiotic
usage. It could support global target setting to reduce the overuse
and misuse of antibiotics in the future, both in people and in
animals.
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